Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Renascience Inc. (4889.T)
Tokyo, JP
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.57% | +40.81% | +17.15% | -0.41% | -11.82% | +18.54% | +43.56% | +209.69% | +105.08% | +105.08% | +105.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-48.3% Q1'26: -57.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-362.2% Q1'26: -95.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-457.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-520.6% Q1'26: -356.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +508.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: +4.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
139.33M
est: 122.00M (+14.2%)
|
100.55M
est: 300.00M (-66.5%)
|
194.17M
est: 400.00M (-51.5%)
|
132.69M
est: 600.00M (-77.9%)
|
1.00B
1.00B – 1.00B
+66.7% YoY
|
| EBITDA |
-244.65M
est: -59.20M (-313.3%)
|
-332.49M
est: -145.56M (-128.4%)
|
-250.50M
est: -194.08M (-29.1%)
|
143.83M
est: -291.13M (+149.4%)
|
-485.21M
-485.21M – -485.21M
-66.7% YoY
|
| EBIT |
-247.72M
est: -59.53M (-316.1%)
|
-333.87M
est: -146.38M (-128.1%)
|
-252.34M
est: -195.18M (-29.3%)
|
143.76M
est: -292.77M (+149.1%)
|
-487.94M
-487.94M – -487.94M
-66.7% YoY
|
| Net Income |
-254.29M
est: -414.40M (+38.6%)
|
-335.80M
est: -311.44M (-7.8%)
|
-258.34M
est: -259.32M (+0.4%)
|
113.43M
est: 155.08M (-26.9%)
|
104.24M
104.24M – 104.24M
-32.8% YoY
|
| SGA |
193.00M
est: 177.31M (+8.8%)
|
185.00M
est: 436.01M (-57.6%)
|
167.00M
est: 581.35M (-71.3%)
|
307.77M
est: 872.02M (-64.7%)
|
1.45B
1.45B – 1.45B
+66.7% YoY
|
| EPS |
-22.33
est: -32.60 (+31.5%)
|
-26.42
est: -24.50 (-7.8%)
|
-20.32
est: -20.40 (+0.4%)
|
8.92
est: 12.20 (-26.9%)
|
8.20
8.20 – 8.20
-32.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mituaki Kamata | Executive Vice President & Director | — | male |
| Sho Kato | Executive Officer | — | male |
| Toshio Miyata | Chief Executive Officer & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4889.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
